Solid biosciences reports fourth quarter and full year 2024 financial results and provides business updates

- duchenne : reported positive initial data from inspire duchenne trial of next-generation duchenne gene therapy candidate, sgt-003; in mid-2025, company plans to request a u.s. food and drug administration (fda) meeting to discuss potential accelerated approval pathways -
SLDB Ratings Summary
SLDB Quant Ranking